LQDA - Liquidia Technologies, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
4.0100
+0.0100 (+0.25%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close4.0000
Open3.9900
Bid3.5000 x 900
Ask0.0000 x 900
Day's Range3.9000 - 4.1300
52 Week Range3.2500 - 38.4600
Volume88,924
Avg. Volume86,392
Market Cap74.76M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.5090
Earnings DateOct 29, 2019 - Nov 4, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est33.50
Trade prices are not sourced from all markets
  • GlobeNewswire

    Liquidia Technologies Appoints Industry Veteran Dr. Joanna Horobin to Board of Directors

    “Joanna is an excellent addition to Liquidia’s Board as she is an industry veteran in drug development and commercialization across several therapeutic areas,” said Stephen Bloch, M.D., Chairman of the Board.

  • GlobeNewswire

    Liquidia to Present at H.C. Wainwright Healthcare Conference

    RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2019 -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company,.

  • Morrisville's Liquidia seeks partner as it prepares to launch new drug
    American City Business Journals

    Morrisville's Liquidia seeks partner as it prepares to launch new drug

    A Morrisville-based drug developer with a late-stage asset is on the market looking for a partner – a potential lucrative opportunity as it sures up its drug pipeline.

  • GlobeNewswire

    Liquidia to Present at Wedbush PacGrow Healthcare Conference

    RESEARCH TRIANGLE PARK, N.C., Aug. 08, 2019 -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company,.

  • GlobeNewswire

    Liquidia Technologies Reports Second Quarter 2019 Financial Results and Provides Corporate Update

    On Track for Planned New Drug Application (NDA) Submission for LIQ861 in Late 2019 Continued Pipeline Progress Leveraging Proprietary PRINT® Technology Management to Host.

  • GlobeNewswire

    Liquidia to Report Second Quarter 2019 Financial Results and Provide Corporate Update on August 8, 2019

    RESEARCH TRIANGLE PARK, N.C., Aug. 02, 2019 -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the.

  • Could Liquidia Technologies, Inc.'s (NASDAQ:LQDA) Investor Composition Influence The Stock Price?
    Simply Wall St.

    Could Liquidia Technologies, Inc.'s (NASDAQ:LQDA) Investor Composition Influence The Stock Price?

    Every investor in Liquidia Technologies, Inc. (NASDAQ:LQDA) should be aware of the most powerful shareholder groups...

  • Hedge Funds Have Never Been This Bullish On Liquidia Technologies, Inc. (LQDA)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Liquidia Technologies, Inc. (LQDA)

    Is Liquidia Technologies, Inc. (NASDAQ:LQDA) a good bet right now? We like to analyze hedge fund sentiment before doing days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy League graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a shortage […]

  • Behind Liquidia's new deal with GSK
    American City Business Journals

    Behind Liquidia's new deal with GSK

    As a Triangle company rapidly approaches filling for approval of its first drug, it has inked a deal with GlaxoSmithKline to bring more drugs up the pipeline behind it.

  • GlobeNewswire

    Liquidia and GSK Restructure Collaboration Agreement

    Liquidia Technologies, Inc. (LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology, today announced that it has amended its collaboration agreement with GlaxoSmithKline (GSK) for the development and commercialization of pharmaceuticals based upon the Company’s proprietary PRINT® technology delivered through the inhalation route of administration. The amended collaboration agreement provides the Company with the right to develop and commercialize three additional PRINT®-based therapeutics delivered via inhalation. Additionally, under the amended collaboration agreement, the Company can acquire rights to pursue additional PRINT®-based programs for inhalation therapy, subject to GSK’s approval.

  • GlobeNewswire

    Liquidia Announces Clinical Update on INSPIRE; Targeting NDA Filing for LIQ861 in Late 2019

    Results from the INSPIRE study indicates that the 75 mcg capsule strength of LIQ861 (single capsule, 1-2 breaths) correlates with the 54 mcg dose of Tyvaso® (9 breaths), the maximum recommended label dose of Tyvaso®. INSPIRE also included a one-directional, crossover sub-study to assess the comparable bioavailability and pharmacokinetics (PK) of single doses of LIQ861 and Tyvaso in 18 PAH patients. The company targets NDA submission in late 2019 that will include additional data generated from ongoing development activities.

  • GlobeNewswire

    Liquidia to Present at Jefferies Healthcare Conference

    RESEARCH TRIANGLE PARK, N.C., June 03, 2019 -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company, announced that Neal.

  • GlobeNewswire

    Liquidia Appoints Seasoned Biopharmaceutical Industry Executive Dr. Richard Katz as Chief Financial Officer

    Liquidia Technologies, Inc. (LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company, today announced the appointment of Richard D. Katz, M.D., as Chief Financial Officer (CFO). Dr. Katz joins Liquidia with more than 20 years of experience in healthcare finance and corporate development. Most recently, he served as CFO at Argos Therapeutics.

  • GlobeNewswire

    Liquidia Announces Poster Presentation at the American Thoracic Society (ATS) International Conference 2019

    Liquidia Technologies, Inc. (LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company, today announced that Nicholas Hill, MD, Chief Pulmonary, Critical Care & Sleep Division, Professor of Medicine at Tufts University School of Medicine, and INSPIRE Principal Investigator, will present a poster highlighting data from Liquidia’s Phase 3 INSPIRE trial of LIQ861 for the treatment of pulmonary arterial hypertension (PAH) at the ATS International Conference in Dallas, Texas. The poster will include data on tolerability of LIQ861 and selected exploratory endpoints at two months of treatment, split by New York Heart Association Functional Class.

  • GlobeNewswire

    Liquidia Technologies Reports First Quarter 2019 Financial Results and Provides Corporate Update

    Recent Phase 3 Data Highlight Clinical Relevance of LIQ861 in Treating Pulmonary Arterial HypertensionOn Track for Planned New Drug Application (NDA) Submission for LIQ861 in.

  • GlobeNewswire

    Liquidia Technologies to Report First Quarter 2019 Financial Results and Provide Corporate Update on May 2, 2019

    RESEARCH TRIANGLE PARK, N.C., April 23, 2019 -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the.

  • GlobeNewswire

    Liquidia Technologies Presents Phase 3 Trial Data for LIQ861 at the ISHLT 39th Annual Meeting & Scientific Sessions

    Liquidia Technologies, Inc. (LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of LIQ861, announced today additional detailed safety and exploratory endpoint findings at the two-month timepoint for the Phase 3 INSPIRE trial. Nicholas Hill, MD, Chief Pulmonary, Critical Care & Sleep Division and Professor of Medicine at Tufts University School of Medicine and INSPIRE Principal Investigator, presented the data at the opening plenary session of the 39th International Society for Heart & Lung Transplantation (ISHLT) Meeting and Scientific Sessions in Orlando, Florida. Liquidia is pursuing approval of LIQ861, an inhalation dry powder formulation of treprostinil that is produced using its PRINT® Technology, as an alternative to current inhaled treprostinil therapy for the treatment of patients with pulmonary arterial hypertension (PAH) (WHO Group 1).

  • GlobeNewswire

    Liquidia Technologies to Present at Needham Healthcare Conference

    RESEARCH TRIANGLE PARK, N.C., April 02, 2019 -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the.

  • GlobeNewswire

    Liquidia Technologies Announces Closing of Offering of Common Stock

    RESEARCH TRIANGLE PARK, N.C., March 25, 2019 -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the.

  • GlobeNewswire

    Liquidia Technologies Announces Pricing of Offering of Common Stock

    RESEARCH TRIANGLE PARK, N.C., March 21, 2019 -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the.

  • Morrisville company looks to Wall Street — again
    American City Business Journals

    Morrisville company looks to Wall Street — again

    Less than a year after its IPO, this Morrisville company wants to raise more cash to fund its core competencies.

  • GlobeNewswire

    Liquidia Technologies Announces Proposed Offering of Common Stock

    Liquidia Technologies, Inc. (LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of patients, today announced that it has commenced an underwritten public offering of 3,000,000 shares of its common stock. All of the shares in the proposed offering will be sold by Liquidia. In addition, Liquidia expects to grant the underwriters a 30-day option to purchase up to an additional 450,000 shares of common stock at the public offering price, less underwriting discounts and commissions.

  • GlobeNewswire

    Liquidia’s LIQ861 Meets Primary Endpoint in Pivotal Phase 3 INSPIRE Study in Patients with Pulmonary Arterial Hypertension

    Liquidia Technologies, Inc. (LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology, today announced top-line results of its pivotal Phase 3 INSPIRE study in patients with pulmonary arterial hypertension (“PAH”) treated with LIQ861, the first inhaled dry powder formulation of treprostinil. Initial analysis indicates the study has met its primary endpoint of safety and tolerability of LIQ861 at the two-month timepoint. Nicholas Hill, MD, Chief Pulmonary, Critical Care & Sleep Division and Professor of Medicine at Tufts University School of Medicine and INSPIRE Principal Investigator, stated: “The top-line analysis of LIQ861 from the INSPIRE study is highly encouraging for physicians and patients.

  • GlobeNewswire

    Liquidia Technologies Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update

    Reported positive interim LIQ861 safety data from its pivotal Phase 3 INSPIRE clinical trialAccepted by FDA into Emerging Technology Program to support review of PRINT®.

  • GlobeNewswire

    Liquidia Technologies to Report 2018 Financial Results and Provide Corporate Update on February 26, 2019

    RESEARCH TRIANGLE PARK, N.C., Feb. 13, 2019 -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the.